Amrubicin hydrochloride for relapsed small-cell lung cancer

Bibliography

• Nair BS, Bhanderi V, Jafri SH. Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clin Med Insights Oncol 2011;5:223-34
   PubMedGoogle Scholar
• Jeremic B. Lung Cancer, Part II. Current status and treatment of small cell lung cancer. Radiation therapy in small cell lung cancer. Hematol Oncol Clin North Am 2004;18:297-308
   PubMedGoogle Scholar
• Ogawara D, Fukuda M, Nakamura Y, et al. Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. Cancer Manag Res 2010;2:191-5
   PubMedGoogle Scholar
• von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7
   PubMed Web of Science ®Google Scholar
• Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989;80:69-76
   PubMedGoogle Scholar
• Morisada S, Yanagi Y, Kashiwazaki Y, et al. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 1989;80:77-82
   PubMedGoogle Scholar
• Hanada M, Noguchi T, Murayama T. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline]. Nihon Yakurigaku Zasshi 2003;122:141-50
   PubMedGoogle Scholar
• Makino Y, Yamamoto N, Sato H, et al. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. Cancer Chemother Pharmacol 2012;69:861-9
   PubMedGoogle Scholar
• Sugiura T, Ariyoshi Y, Negoro S, et al. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Invest New Drugs 2005;23:331-7
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa M, Horikoshi N, et al. Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Invest New Drugs 1989;7:213-18
   PubMedGoogle Scholar
• Rocha Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer–a focus on the evolving role of topotecan. Lung Cancer 2003;40:229-36
   PubMedGoogle Scholar
• Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301. J Clin Oncol 2006;24:5448-53
   PubMed Web of Science ®Google Scholar
• Kaira K, Sunaga N, Tomizawa Y, et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2010;69:99-104
   PubMed Web of Science ®Google Scholar
• Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-6
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603
   PubMedGoogle Scholar
• Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-93
   PubMed Web of Science ®Google Scholar
• Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: north Japan Lung cancer study group trial 0402. J Clin Oncol 2008;26:5401-6
   PubMed Web of Science ®Google Scholar
• Jotte R, Von Pawel J, Spigel D. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer. J Clin Oncol 2011;29:abstract 7000
   Google Scholar
• Salvatorelli E, Menna P, Surapaneni S, et al. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin. J Pharmacol Exp Ther 2012;341:464-73
   PubMedGoogle Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811
   PubMed Web of Science ®Google Scholar
• Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012;109:17034-9
   PubMed Web of Science ®Google Scholar